A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer